BioCentury | Feb 11, 2020
Product Development

Alzheimer’s prevention replays the same amyloid failures as the treatment setting

The Phase II/III DIAN-TU trial of Lilly’s solanezumab and Roche’s gantenerumab was always a long shot, given the previous late-stage failures of both agents in Alzheimer’s trials. Perhaps more surprising is that both compounds remain...
BioCentury | May 4, 2019
Product Development

How the amyloid hypothesis holds its grip

By now, two things are clear about the amyloid hypothesis of Alzheimer’s disease: one is that the amyloid peptide is somehow involved; the other is that it’s a terrible target. β amyloid has had an...
BioCentury | May 4, 2019
Product Development

Amyloid: how did we get here and what can we learn?

Unlike any other theory in drug development, the amyloid hypothesis of Alzheimer’s disease has maintained an almost cult-like following, despite two decades littered with a long line of late-stage failures and not a single success....
BioCentury | Mar 23, 2019
Product Development

Baby steps beyond beta amyloid

Companies are taking steps -- baby steps -- to test new targets in pathways such as neuroinflammation and neuroprotection as a means to treat Alzheimer’s disease. The failure of aducanumab won’t be the final nail...
BioCentury | Mar 22, 2019
Finance

Biogen's lead balloon

Biogen took a 29% haircut to $226.88 on Thursday following its decision to discontinue the Phase III ENGAGE and EMERGE trials of aducanumab for Alzheimer’s disease. The company's stock price has been dragged down 48%...
BC Extra | Mar 21, 2019
Clinical News

Biogen, Eisai discontinuing aducanumab studies in AD

Biogen and Eisai said aducanumab is unlikely to meet the primary endpoints of two Phase III trials to treat early Alzheimer's disease, joining a long list of failed mAbs against β amyloid and putting more...
BC Week In Review | Feb 1, 2019
Clinical News

Roche stops crenezumab trials in early Alzheimer's for futility

The β amyloid hypothesis for treating Alzheimer's disease suffered another setback on Jan. 30 after Roche (SIX:ROG; OTCQX:RHHBY) discontinued a pair of Phase III trials of crenezumab (RG7412) to treat early AD. Roche's Genentech Inc....
BC Extra | Jan 30, 2019
Clinical News

Roche stops crenezumab trials in early Alzheimer’s for futility

The β amyloid hypothesis for treating Alzheimer's disease suffered another setback Wednesday after Roche (SIX:ROG; OTCQX:RHHBY) discontinued a pair of Phase III trials of crenezumab (RG7412) to treat early AD. Roche's Genentech Inc. unit has...
BC Extra | Jul 26, 2018
Company News

Biogen, Eisai AD readout leads to stock dive

Biogen Inc. (NASDAQ:BIIB) sank $39.09 (10%) to $344.74 on Thursday after reporting detailed data from a Phase II trial of Alzheimer's disease candidate BAN2401. Although the data showed that the anti-β amyloid therapy slowed cognitive...
BioCentury | Mar 4, 2017
Product Development

Diagnosing AD trials

A battery of expensive late-stage failures has made it obvious to Alzheimer’s disease companies that more and better diagnostics will be essential to get new disease-modifying therapies to patients. But so far, the approaches being...
Items per page:
1 - 10 of 53